Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-967-7 | CAS number: 3296-90-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- two-generation reproductive toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and well conducted study performed by Environmental Health Research and Testing Inc.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
Materials and methods
- Principles of method if other than guideline:
- The study was performed using the NTP Fertility Assessment by Continuous Breeding (FACB) system. It consists of four related tasks as follows: 1. dose finding. 2. continuous breeding phase. 3. identification of the affected sex. 4 offspring assessment.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,2-bis(bromomethyl)propane-1,3-diol
- EC Number:
- 221-967-7
- EC Name:
- 2,2-bis(bromomethyl)propane-1,3-diol
- Cas Number:
- 3296-90-0
- Molecular formula:
- C5H10Br2O2
- IUPAC Name:
- 2,2-bis(bromomethyl)propane-1,3-diol
- Details on test material:
- Source: Dow Chemical Company, Lot No.: MM05137-636, Purity: Approx 87.3%, Identity of impurities: 2,2-bis(hydroxymethyl)-1-bromo-3-hydroxypropane (6.7%), 2,2-bis(bromomethyl)-1-bromo-3-hydroxypropane (5.5%), 3,3-bis(bromomethyl) oxetane (0.5%), water (3±0.1%).
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Parental: 20 male, 20 female per dose. Age:11 weeks
F1: 20 male, 20 female per dose. Age 64-84 days
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- other: substance was administered in feed
- Details on mating procedure:
- Task 2: 1 male and 1 female per cage. Cohabitation for 14 weeks.
Task 3: 1 male and 1 female per cage. Cohabitation until vaginal plug was detected or for a maximum of 7 days
Task 4: 1 male and 1 female per cage. Cohabitation continued for seven days or until a copulatory plug was found. - Details on analytical verification of doses or concentrations:
- Range finding study Task 1: 0, 0.025, 0.05, 0.1, 0.25, 0.5 % w/w
Cohabitation study Task 2: 0, 0.1, 0.2, 0.4 % w/w
Crossover Mating Study Task 3: No chemical treatment during the mating period. 0, 0.4 % w/w during post-mating holding period.
Second Generation Study Task 4: 0, 0.1, 0.2, 0.4 % w/w. - Duration of treatment / exposure:
- Premating exposure period for males: Parental (Task 2): 7 days
F1 (Task 4): 64-84 days
Premating exposure periods for females: Parental (Task 2): 7 days
F1 (task 4): 64-84 days. - Frequency of treatment:
- Daily, ad libitum
- Details on study schedule:
- Task 1: 2 weeks
Task 2: 1 week pre-treatment, 14 weeks cohabitation, and 3 weeks holding period.
Task 3: 1 week cohabitation (maximum), and 3 weeks holding period.
Task 4: 74±10 days premating, 7 days (maximum cohabitation), and 3 weeks holding period.
- No. of animals per sex per dose:
- Parental: 20 male, 20 female per dose. Age 11 weeks
F1: 20 male, 20 female per dose. Age: 64-84 days. - Details on study design:
- Control group:
Task 1: 8 males, 8 females; vehicle control
Task 2: 40 males, 40 females; vehicle control
Task 3: 20 males, 20 females; vehicle control
Task 4: 20 males, 20 females; vehicle control
Standardization of litters: No
Examinations
- Parental animals: Observations and examinations:
- Task 2 parental body weights were measured on days-7 (start of dosing), 0 (start of cohabitation), 7, 28, 84 and 112.
- Oestrous cyclicity (parental animals):
- Studied during Task 3
- Sperm parameters (parental animals):
- Sperm motility, sperm counts per "g" caudal tissue, and the incidence of abnormal sperm were examined at the end of Task 3
- Litter observations:
- At least twice per day: Loss of hair, diarrhoea, wounds, hyperactivity, inactivity, tearing or ocular discharge, paralysis, nasal discharge, blood in cage and or/ on animal, abnornal posture or death.
- Postmortem examinations (offspring):
- Female-liver, kidney, lymph nodes, mammary glands, ovary, oviduct, uterus, vagina, urinary bladder and skeletal muscle; Male-kidney, liver, epididymis, prostate gland, seminal vesicles, skin, testes and urinary bladder.
- Statistics:
- The Cochran-Armitage test was used in Task 2 to assess dose-related trends in fertility. Days between litters were evaluated by Shirley’s test. In Task 3 a c 2 test for homogeneity was used to test for an overall difference in fertility among the cross-mated groups. Pairwise comparisons between control and dosed groups were determined by the Fisher’s exact test. Dose group means for the proportion of live pups and sex ratio of pups were tested for overall differences by the Kruskal-Wallis test and for ordered differences by the Jonckheere test. Pairwise comparisons of treatment group means were determined by the Wilcoxon-Mann-Whitney U test. Differences in average pup weight were investigated using analysis of covariance (ANCOVA), using avaerage litter size inclusive of live and dead pups as covariant. Pairwise comparisons were performed using a two-tailed t test. For organ weights, analysis of covariance was performed to determine least squares treatment group means, which were then tested for overall and pairwise equality by two-sided F and t tests, respectively. The Kruskal-Wallis and Wilcoxon-Mann-Whitney U tests were also employed in the analysis of unadjusted body and organ weights.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- After 14 weeks of treatment the weight gain for males in the 0, 0.1, 0.2, and 0.4 % dose groupd was 12, 10, 8, and 0% respectively. In fact, mice in th 0.4% dose group lost weight during the first few weeks of treatment and later regained it. Animals in all 3 dose groups consistently weighed less than the control group. The difference was most apparent at the 0.4% dose level.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- Significant decrease (p<0.01) in the mean number of litters per fertile pair at the 0.4% BBMP level.
Other reproductive parameters significantly affected (p<0.01) at this dose level were : the total number of live pups (male, female) per litter, the proportion of the pups born alive, and the adjusted live pups weight.
At the 0.2% dose level, both absolute (except for female pups) and adjusted live pups weights were significantly decreased (p<0.05).
BBMP was significantly toxic at 0.2% and 0.4% dose levels as was revealed by the average dam weight by litter.
Details on results (P0)
Effect levels (P0)
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- F0
- Effect level:
- 0.1 other: %
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive performance
Target system / organ toxicity (P0)
- Key result
- Critical effects observed:
- no
Results: P1 (second parental generation)
General toxicity (P1)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- no effects observed
Reproductive function / performance (P1)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- effects observed, treatment-related
Effect levels (P1)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 0.1 other: %
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive performance
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not specified
- Mortality / viability:
- not specified
- Body weight and weight changes:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
Details on results (F1)
Effect levels (F1)
open allclose all
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- F0
- Generation:
- F1
- Effect level:
- 0.1 other: %
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: reproductive performance
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- F1
- Generation:
- F1
- Effect level:
- 0.1 other: %
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: reproductive performance
Results: F2 generation
General toxicity (F2)
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Pups in the 3 dose groups were smaller than the control group at weaning as well as through maturation.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There was no apparent difference with respect to average daily feed consumptio in the control and 3 dose groups.
- Histopathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Kidney and liver
Effect levels (F2)
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- F1
- Generation:
- F2
- Effect level:
- 0.1 other: %
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The substance administered in feed at the 0.4% dose level adversely affected reproduction in CD1
mice. Continued treatment at this dose level also resulted in a significant drop in body weight. The crossover mating study showed that it was the reproductive performance of female mice that was affected by treatment with the substance at the 0.4% dose level. The number of live pups per litter delivered by the 0.4% female x control male group being significantly lower than the 0.4% male x control female group. The reproductive performance of second generation CD-1 mice exposed to the substance at the 0.4% dose level was adversely affected with respect to the number of live pups per litter and the adjusted live pup weight. Second generation animals in the 0.4% group weighed less than the control group at weaning, through maturation and at necropsy.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
